Clinical Trial Update: A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating the effect of itraconazole on pathologic complete response rates in resectable esophageal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Gastroesophageal Junction Carcinoma

Drugs mentioned

• Itraconazole (Itraconazole)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING